BioCardia, Inc. (BCDA)

US — Healthcare Sector
Peers: AVTE  ADAG  ACRV  RZLT  ANTX  ZIVO  THRX  ERAS  FBRX  AMTI  ABVC  INDP  KTTA  BTTX  ANEB  MLYS  NGENF  PTIX  MIRO 

Automate Your Wheel Strategy on BCDA

With Tiblio's Option Bot, you can configure your own wheel strategy including BCDA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol BCDA
  • Rev/Share -0.0119
  • Book/Share -0.3279
  • PB -6.1607
  • Debt/Equity -0.5592
  • CurrentRatio 0.3627
  • ROIC 8.4824

 

  • MktCap 10459338.0
  • FreeCF/Share -1.7516
  • PFCF -1.2881
  • PE -1.116
  • Debt/Assets 0.3924
  • DivYield 0
  • ROE -307.9266

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025
BCDA
Published: May 21, 2025 by: GlobeNewsWire
Sentiment: Neutral

SUNNYVALE, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that BioCardia's CEO, Peter Altman, Ph.D., will participate in a fireside chat at the Alliance Global Partners Virtual Healthcare Company Showcase hosted by Jim Molloy, Managing Director, Equity Research Biotechnology & Specialty Pharmaceuticals at A.G.P., on May 21, 2025.

Read More
image for news BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025
Insider Buying Surges in May. Especially These 5 Stocks
BCDA, MSTR, SON, TRS, WBA
Published: May 07, 2025 by: 24/7 Wall Street
Sentiment: Neutral

The Securities Act of 1934 established many of the US rules for the securities market in the aftermath of the 1929 Stock Market Crash that ushered in The Great Depression.

Read More
image for news Insider Buying Surges in May. Especially These 5 Stocks
BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study
BCDA
Published: April 11, 2025 by: GlobeNewsWire
Sentiment: Neutral

CardiAMP HF II is Evaluating the CardiAMP™ Cell Therapy Product for Treating Patients with Ischemic Heart Failure of Reduced Ejection Fraction and Elevated Markers of Cardiac Stress

Read More
image for news BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study
BioCardia's Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today
BCDA
Published: March 31, 2025 by: GlobeNewsWire
Sentiment: Neutral

SUNNYVALE, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today clarifies that two-year CardiAMP-HF results will be addressed in a conference call scheduled for today, Monday, March 31, 2025 at 4:30pm EDT. The press release earlier this morning incorrectly noted the call would be held at 4:30pm PDT.

Read More
image for news BioCardia's Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today
BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System
BCDA
Published: March 10, 2025 by: GlobeNewsWire
Sentiment: Neutral

SUNNYVALE, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that the Japan Patent Office has granted Japanese Patent No. 7641330 titled “Radial and Transendocardial Delivery Catheter” with a patent term that will expire on or after September 30, 2034.

Read More
image for news BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System

About BioCardia, Inc. (BCDA)

  • IPO Date 1996-11-13
  • Website https://www.biocardia.com
  • Industry Biotechnology
  • CEO Dr. Peter A. Altman Ph.D.
  • Employees 17

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.